FY2029 Earnings Estimate for TRVI Issued By B. Riley

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Stock analysts at B. Riley issued their FY2029 earnings per share estimates for shares of Trevi Therapeutics in a research note issued on Thursday, February 13th. B. Riley analyst M. Mamtani forecasts that the company will earn ($0.95) per share for the year. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics’ FY2029 earnings at ($0.95) EPS.

Several other research firms have also commented on TRVI. D. Boral Capital restated a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Trevi Therapeutics in a research note on Thursday, December 12th. Finally, HC Wainwright increased their price target on Trevi Therapeutics from $6.00 to $7.50 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $4.07 on Monday. The business’s fifty day moving average price is $3.96 and its 200-day moving average price is $3.34. The stock has a market capitalization of $312.84 million, a price-to-earnings ratio of -9.25 and a beta of 0.88. Trevi Therapeutics has a 1-year low of $2.13 and a 1-year high of $4.68.

Hedge Funds Weigh In On Trevi Therapeutics

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in shares of Trevi Therapeutics by 220.6% during the third quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock worth $336,000 after acquiring an additional 69,167 shares during the period. Geode Capital Management LLC increased its position in shares of Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock worth $4,223,000 after acquiring an additional 117,418 shares during the period. Barclays PLC increased its position in shares of Trevi Therapeutics by 180.8% during the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock worth $319,000 after acquiring an additional 61,317 shares during the period. State Street Corp increased its position in shares of Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock worth $3,183,000 after acquiring an additional 53,051 shares during the period. Finally, BNP Paribas Financial Markets increased its position in shares of Trevi Therapeutics by 130.9% during the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the period. 95.76% of the stock is owned by hedge funds and other institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.